Neurizon Therapeutics (ASX:NUZ) submitted a formal response to the US Food and Drug Administration (FDA) regarding the clinical hold on its investigational new drug application for NUZ-001, its lead therapy for amyotrophic lateral sclerosis, according to a Friday filing with the Australian bourse.
The response includes 28-day pharmacokinetic data from studies in rats and dogs to address the FDA's request for more comprehensive animal exposure data to support the safety margins of NUZ-001 and its primary sulfone metabolite, the filing said.
The review is now underway, and the company expects to receive formal feedback within 30 calendar days, per the filing.
Shares rose 19% in morning trade on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.